Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era

Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Herein, we have analyzed the SEER database to assess the survival outcome of metastatic prostate c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Isaac E., Jang, Thomas L., Kim, Sinae, Lee, David Y., Kim, Daniel D., Singer, Eric A., Ghodoussipour, Saum, Stein, Mark N., Aron, Monish, Dall’Era, Marc A., Yi Kim, Isaac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607264/
https://www.ncbi.nlm.nih.gov/pubmed/34713977
http://dx.doi.org/10.1002/cam4.4074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607264/
https://www.ncbi.nlm.nih.gov/pubmed/34713977
http://dx.doi.org/10.1002/cam4.4074

Ejemplares similares